[go: up one dir, main page]

MX2018015350A - Anticuerpos anti-gitr y sus usos. - Google Patents

Anticuerpos anti-gitr y sus usos.

Info

Publication number
MX2018015350A
MX2018015350A MX2018015350A MX2018015350A MX2018015350A MX 2018015350 A MX2018015350 A MX 2018015350A MX 2018015350 A MX2018015350 A MX 2018015350A MX 2018015350 A MX2018015350 A MX 2018015350A MX 2018015350 A MX2018015350 A MX 2018015350A
Authority
MX
Mexico
Prior art keywords
gitr antibodies
methods
gitr
antibodies
glucocorticoid
Prior art date
Application number
MX2018015350A
Other languages
English (en)
Inventor
Delfino Frank
Skokos Dimitris
Wang Bei
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018015350A publication Critical patent/MX2018015350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente al receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y métodos para usarlos, incluidos, por ejemplo, métodos de tratamiento que los usan.
MX2018015350A 2016-06-10 2017-06-09 Anticuerpos anti-gitr y sus usos. MX2018015350A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018015350A true MX2018015350A (es) 2019-08-26

Family

ID=59078260

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015350A MX2018015350A (es) 2016-06-10 2017-06-09 Anticuerpos anti-gitr y sus usos.
MX2022014695A MX2022014695A (es) 2016-06-10 2018-12-10 Anticuerpos anti-gitr y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014695A MX2022014695A (es) 2016-06-10 2018-12-10 Anticuerpos anti-gitr y sus usos.

Country Status (19)

Country Link
US (3) US10738126B2 (es)
EP (2) EP4344748A3 (es)
JP (2) JP7162535B2 (es)
KR (1) KR102495601B1 (es)
CN (1) CN109563170B (es)
AU (1) AU2017278193B9 (es)
BR (1) BR112018075434A2 (es)
CA (1) CA3027121A1 (es)
CL (1) CL2018003515A1 (es)
CO (1) CO2018013298A2 (es)
IL (1) IL263273B2 (es)
MA (1) MA45233A (es)
MX (2) MX2018015350A (es)
MY (1) MY200162A (es)
PH (1) PH12018502502A1 (es)
SG (1) SG11201810525XA (es)
UA (1) UA128687C2 (es)
WO (1) WO2017214548A1 (es)
ZA (1) ZA201807920B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
MA45233A (fr) 2016-06-10 2019-04-17 Regeneron Pharma Anticorps anti-gitr et leurs utilisations
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
EP4600375A3 (en) 2016-12-09 2025-11-12 Regeneron Pharmaceuticals, Inc. Systems and methods for sequencing t cell receptors and uses thereof
SG11202008784RA (en) * 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
MA54945A (fr) 2019-02-12 2021-12-22 Regeneron Pharma Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
EP4085074A4 (en) * 2020-01-02 2024-05-15 Nanjing GenScript Biotech Co., Ltd. ANTI-GITR ANTIBODIES AND THEIR USES
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
PH12022552295A1 (en) 2020-03-06 2024-01-22 Regeneron Pharma Anti-gitr antibodies and uses thereof
CN116761622A (zh) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 药物产品及其用途
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
EP4339209A4 (en) * 2021-05-10 2025-05-28 MediMabbio Inc. ANTI-GITR ANTIBODIES AND THEIR USES
KR20240155275A (ko) 2022-03-15 2024-10-28 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 항 글루코코르티코이드 유도 tnfr 관련(gitr) 단백질 항체 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP4440344B2 (ja) 1996-08-16 2010-03-24 シェーリング コーポレイション 哺乳動物細胞表面抗原；関連試薬
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
ES2320285T3 (es) 1997-11-18 2009-05-20 Genentech, Inc. Polipeptido dna19355, un homologo del factor de necrosis tumoral.
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
HRP20120175T1 (hr) 2006-06-02 2012-03-31 Regeneron Pharmaceuticals Antitijela s visokim afinitetom za humani il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA3067609A1 (en) 2009-09-03 2011-03-10 Merck Sharp & Dohme Corp. Anti-gitr antibodies
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
US9175308B2 (en) 2011-10-07 2015-11-03 Mie University Chimeric antigen receptor
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
RS59643B1 (sr) 2014-06-06 2020-01-31 Bristol Myers Squibb Co Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
CA2962976A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
MA45233A (fr) 2016-06-10 2019-04-17 Regeneron Pharma Anticorps anti-gitr et leurs utilisations

Also Published As

Publication number Publication date
AU2017278193B2 (en) 2024-01-18
CN109563170B (zh) 2023-10-13
MX2022014695A (es) 2022-12-16
CA3027121A1 (en) 2017-12-14
US10738126B2 (en) 2020-08-11
IL263273B1 (en) 2025-06-01
UA128687C2 (uk) 2024-10-02
SG11201810525XA (en) 2018-12-28
JP2022159476A (ja) 2022-10-17
PH12018502502A1 (en) 2019-04-08
MA45233A (fr) 2019-04-17
NZ748619A (en) 2024-05-31
AU2017278193A1 (en) 2018-12-13
US11414494B2 (en) 2022-08-16
AU2017278193B9 (en) 2024-02-01
EP4344748A2 (en) 2024-04-03
ZA201807920B (en) 2024-01-31
CL2018003515A1 (es) 2019-03-08
JP7162535B2 (ja) 2022-10-28
US20210147565A1 (en) 2021-05-20
EP3468999A1 (en) 2019-04-17
CN109563170A (zh) 2019-04-02
IL263273B2 (en) 2025-10-01
IL263273A (en) 2018-12-31
US20170355774A1 (en) 2017-12-14
EP3468999B1 (en) 2024-01-10
KR102495601B1 (ko) 2023-02-06
BR112018075434A2 (pt) 2019-03-19
MY200162A (en) 2023-12-09
JP2019521098A (ja) 2019-07-25
KR20190020297A (ko) 2019-02-28
WO2017214548A1 (en) 2017-12-14
CO2018013298A2 (es) 2019-02-19
EP4344748A3 (en) 2024-06-12
US20230042324A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
MX2016015614A (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112017006825A2 (pt) anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
HUE061874T2 (hu) Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX2018003629A (es) Anticuerpos anti-pd1 y metodos de uso.
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
CL2016001871A1 (es) Anticuerpos humanos para pd-1
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
UY35399A (es) Conjugados de fármacos con anticuerpos
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
PE20180171A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos